Typical Cancer Case Study

University study of BACO efficacy against Cancer in vivo, Instituto Genesis West – Providia

A fresh capillary blood sample was taken at a time according to protocol to be examined as live blood sample under Phase Contrast, Dark Field and Direct Illumination at 40 X 40 X plus 3.5 X and 17 X magnifications. A second – drop was taken for Clot Retraction Analysis. The results are recorded on the data sheets included in the report.

Case Study # 1 – Female, Advanced Breast Cancer

A female age 37 with the following condition;

• Breast Cancer metastasized into the bones (ribs, lumbar and thoracic vertebrae)
• History of bilateral mastectomy and chemotherapy
• History of bilateral breast implants
• Macrocytic anemia

Note: The patient presented a bacterial infection the day when the sample was taken, adding to the baseline pathology.

Analysis of the effects of BACO in blood before and during treatment in vivo

While in the clinic, the patient received BACO as well as a combination of therapies used to enhance her treatment program.

1. Protein linkage was elevated at the beginning, followed by a sustained low level towards the end of the study. Comparing this pattern with the rouleaux formation that was elevated at the beginning and low at the end, it can be assumed that this resulted in diminished erythrocyte aggregation. The readings immediately after the BACO dosage showed little increase in these three patterns. This result may be due to a pH variance stimulated by BACO.
2. On arrival the patients’ poikilocytosis and anisocytosis were seen to be less as compared to following readings. The second reading recorded (+ +) this being before the administration of the first dose of BACO. Therefore, it can be assumed that there is no relationship between BACO and progressive anemia, BACO therefore, does not affect healthy red cells in vivo.
3. By comparing the first and last sample, it is seen that liver stress decreased. This was measured by the presence of spicules. There was a small increase immediately after the first dose of BACO, thereafter stabilized at a low level.
4. The sample was viable for three days. The rouleaux average remained the same as the control as well as the aggregation (+ + +), with predominance in the area where the BACO made contact with the blood.

Final analysis of BACO in vivo Cancer Study Results

In the following report, the effects that BACO had in the patient’s blood are discussed, by presenting a consecutive analysis of fresh blood on different days. This records data before starting the BACO (consisting of two dates), date after the first doses (consisting of one date), date after the second dosage (consisting of two dates), and data after the third dosage (consisting of one date).

In the in vitro samples, liver stress could not be interpreted, as the metabolic process could not be measured, but only the blood chemical reactions. Therefore, it can be assumed that BACO may have a liver protection function. More studies must be completed.

• The high cholesterol observed in the beginning of the study showed a sudden decrease immediately after the second dose of BACO, from (+ + +) to (+) in a period of less than a month.
• Uric Acid readings were similar to that of the cholesterol, decreasing from (+ +) to (+). This also coincided with a clinical pain relief.
• Target Cells were seen with (+ + +) in the second sample taken, and decreased to (+) at the end of the study. This means a decrease in the parasitic condition.
• The presence of parasitic forms in the plasma, and bacterial activity presented by the patient on arrival was (+ + +), after the first dose decreased to (+) and then to zero.
• The presence of pathogenic Somatids at the beginning of the study varied from rod, to mycelial and asci forms. These were collected by the second dose of BACO. There is no relationship between the diminishing of pathogenic forms and the use of antibiotics, but there is a decrease when BACO is used. The amount of non-pathogenic Somatids was zero at the beginning, and starting to increase with the presence of the double spores that were in the limit of becoming pathogenic, just prior to the second dose. This pattern was stable until the end of the study.
• The cellular immune system activity was low, as was the white cell proportion, with predominance of neutrophils and eosinophils in the first reading. This slowly improved, starting with better proportions of white cells and continuing with better activity. This level of activity was sustained until the end of the study. This corresponds to the in vitro analysis. It can therefore be assumed that there is an immune-stimulating response action from BACO both in the in vitro and the in vivo experiments.
• There was mild aggression of thrombocytes with high and low peaks at different times. By the second dose there was larger amount of thrombocytes, probably due to stimulated release from natural deposits rather than to an over-production. This finding is not of clinical importance.
• Possible allergies that decreased from high to moderate.
• Bowel/intestine pattern was seen after the second does, but not seen again.
• Cellular immune system activity was enhanced both in Vitro and in Vivo.
• White cell proportions were balanced and the phagocytes improved their function, BACO may have a factor which should be studied further to comprehend its mode of action.
• There reversal of Somatids into a non-pathogenic cycle and the disappearance of target cells is evidence of a cellular immune system improvement. Further research should be undertaken to determine if there is an opposing involvement.
• Malignancy and metastatic pattern decreased.
• There was a presence of spherocytes on the last day.
• Whereas there was a very elevated bacterial infection at the beginning, the level reduced to (+) by the fourth day.
• Crenocytes levels were elevated by the second day Vacuolae dendroids appeared by the third day.